We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Nanosponge Vaccine Protects Mice from MRSA Toxin

By LabMedica International staff writers
Posted on 10 Dec 2013
A novel vaccine based on "nanosponges" that sequester toxic, pore-forming toxoids—such as that produced by MRSA (methicylin resistant Staphylococcus aureus)—permits presentation of these toxins to immune system defensive cells without danger of damaging them.

It is not possible to deliver a native pore-forming toxin to immune cells without damaging the cells. More...
However, the heating or chemical processing required to neutralize the toxin can compromise the toxin's structural integrity and reduce the value of the vaccine.

To get around this problem, investigators at the University of California, San Diego (USA) developed "nanosponges.” These are biocompatible particles made of a polymer core wrapped in a red blood cell membrane. The red blood cell coating allows the nanosponge to incorporate and hold I alpha-hemolysin toxin without compromising the toxin’s structural integrity through heating or chemical processing. Despite being intact structurally, the trapped toxoid is rendered incapable of damaging other cells.

A paper published in the December 1, 2013, online edition of the journal Nature Nanotechnology presented results from experiments in which nanosponges loaded with toxoid were used to protect mice from MRSA infection. After one injection of the vaccine, 50% of the nanosponge-treated animals survived as compared to fewer than 10% of mice that had been vaccinated with heat-inactivated toxoid. An additional two booster shots increased the survival rate for the nanosponge-vaccinated animals to 100% compared to 90% for those vaccinated with the heat-treated toxin.

"The more you heat it, the safer the toxin is, but the more you heat it, the more you damage the structure of the protein," said senior author Dr. Liangfang Zhang, professor of nanoengineering at the University of California, San Diego. "And this structure is what the immune cell recognizes, and builds its antibodies against. Before this there was no way you could deliver a native toxin to the immune cells without damaging the cells, but this technology allows us to do this."

"The nanosponge vaccine was also able to completely prevent the toxin's damages in the skin, where MRSA infections frequently take place," said Dr. Zhang. "The particles work so beautifully that it might be possible to detain several toxins at once on them, creating one vaccine against many types of pore-forming toxins, from Staphylococcus to snake venom."

Related Links:

University of California, San Diego



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Candida Glabrata Test
ELIchrom Glabrata
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.